COMPANY

Diasome Pharmaceuticals

HQ: Cleveland, OH source · diasome.com ↗ · Midwest

Keywords: metabolic diabetes mellitus obesity metabolic diseases Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus Type1 Diabetes Mellitus

Location: Cleveland, OH · source · Oct 15, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series C · amount not disclosed · announced Dec 7, 2023 Company release ↗
Source quote
- Dec 7, 2023 · Company release ↗
  “-- Diasome Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company that leverages a novel hepatocyte cell targeting platform to develop innovative therapies for diabetes, obesity, and other metabolic disorders, has announced the first closing of its Series C financing today”

From the company’s own releases; this list is partial. All raises and deals

Dec 28, 2023 Trial start 2: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec source ↗
Dec 7, 2023 Raise Series C · amount not disclosed source ↗
Mar 18, 2019 Trial start Phase 2: Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec source ↗
May 18, 2017 Trial start Phase 2: 21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus source ↗
Apr 18, 2017 Trial start Phase 2: Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control source ↗
Sep 17, 2007 Trial start —: A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus source ↗
2016-06 Trial start Phase 2: Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1) source ↗
2008-12 Trial start Phase 2/Phase 3: Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06238778	Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec	2	Completed	Dec 28, 2023	Oct 27, 2025 (actual)
NCT00814294	Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus	Phase 2/Phase 3	Completed	2008-12	2009-09 (actual)
NCT00521378	A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus	Not listed	Completed	Sep 17, 2007	Oct 6, 2007 (actual)
NCT03938740	Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec	Phase 2	Completed	Mar 18, 2019	Dec 6, 2019 (actual)
NCT03096392	Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control	Phase 2	Completed	Apr 18, 2017	Nov 15, 2017 (actual)
NCT02794155	Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)	Phase 2	Completed	2016-06	Apr 28, 2018 (actual)
NCT03156361	21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus	Phase 2	Completed	May 18, 2017	Jan 15, 2018 (actual)